Mode
Text Size
Log in / Sign up

Post-translational modifications drive drug resistance in hepatocellular carcinoma, systematic review findsChemical Changes in Proteins May Help Overcome Drug Resistance in Liver Cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider PTMs as potential targets for overcoming drug resistance in HCC, but evidence is mechanistic.

This systematic review examines the role of post-translational modifications (PTMs) in hepatocellular carcinoma (HCC), specifically focusing on how they contribute to therapeutic resistance. The scope covers five major PTM types: phosphorylation, ubiquitination, acetylation, lactylation, and glycosylation. The review synthesizes mechanistic evidence from preclinical and translational studies, though no quantitative pooled analysis is reported.

The key finding is that PTMs modulate liver cancer cell responses to a broad range of treatments, including chemotherapy, targeted therapy, immunotherapy, and local therapies. This suggests that PTMs are central to the development of resistance across multiple therapeutic modalities. The authors propose that targeting these modifications could serve as a strategy for precision therapy in drug-resistant HCC.

The review does not report effect sizes, patient outcomes, or adverse events, and limitations are not explicitly stated. Therefore, the clinical applicability is preliminary, and the findings should be interpreted as hypothesis-generating rather than practice-changing.

For clinicians, the review reinforces the complexity of drug resistance in HCC and highlights emerging molecular targets. However, no direct clinical recommendations can be made from this evidence alone. Future research should focus on validating PTM-based biomarkers and therapeutic targets in clinical settings.

How this fits prior evidence

This systematic review extends prior coverage by providing a mechanistic framework for drug resistance in HCC. It complements earlier findings that NRF2 signaling promotes multidrug resistance and that metabolic risk factors increase HCC risk, by identifying PTMs as a common pathway that may modulate responses to therapy. It also aligns with the observation that PD-(L)1 plus VEGF antibody is favorable for overall survival, as PTMs may influence immunotherapy efficacy. However, this review does not provide quantitative effect sizes, so it does not directly confirm or contrast the diagnostic accuracy of radiomics or the prognostic value of the Immune Health Index.

Liver cancer can be very difficult to treat because some tumors stop responding to standard treatments. One reason for this is that the cancer cells change how their proteins behave, making it harder for medicine to work effectively.

Researchers are studying specific chemical changes called post-translational modifications. These include processes like phosphorylation and acetylation. These changes act like switches that can turn certain proteins on or off, affecting how the cancer cells react to chemotherapy and other targeted drugs.

By understanding these chemical switches, doctors may find new ways to treat patients. If they can block the specific modifications that help cancer cells survive, they might be able to make current treatments more effective for people with resistant liver cancer.

These findings point toward new ways to create personalized medicine. Instead of a one-size-fits-all approach, doctors could target the specific protein changes that allow a patient's cancer to grow and resist treatment.

What this means for you:
Specific chemical changes to proteins may provide new targets to help treat liver cancer that resists standard drugs.

Common questions

What are post-translational modifications?

They are chemical changes that happen to proteins after they are made. Think of them as tiny tags that can turn a protein on or off. In liver cancer, these tags can help cancer cells survive treatments. The review looked at five types: phosphorylation, ubiquitination, acetylation, lactylation, and glycosylation.

How do these modifications affect liver cancer treatment?

The review found that these modifications can change how liver cancer cells respond to different treatments, including chemotherapy, targeted therapy, immunotherapy, and local therapies. They can make cancer cells resistant, meaning the treatment doesn't work as well. Understanding this could help doctors find ways to overcome resistance.

Is this a new treatment for liver cancer?

No, this is not a new treatment. It's a review of existing research that explains how cancer cells resist treatment. The findings suggest that these modifications could be targets for future precision therapies, but more research is needed before any new treatment is available. Always talk to your doctor about current options.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
Hepatocellular carcinoma (HCC), a malignancy with high global morbidity and mortality, has therapeutic resistance as a major focus of both clinical and basic research. In recent years, protein post-translational modifications (PTMs), key regulators of intracellular protein function and cell signaling, play critical roles in therapeutic resistance in liver cancer. Current studies indicate that diverse PTMs—including phosphorylation, ubiquitination, acetylation, lactylation, and glycosylation—modulate liver cancer cell responses to chemotherapy, targeted therapy, immunotherapy and local therapies. This review systematically summarizes the molecular mechanisms and common pathways through which PTMs contribute to therapeutic resistance in liver cancer, explores PTM-mediated mechanism underlying tumor persistence and distant recurrence,examines how PTM-targeted strategies may reverse resistance, and discusses the challenges and prospects of these therapeutic approaches in clinical practice. By integrating current research, this review aims to provide a theoretical basis and potential targets for precision therapy of drug-resistant liver cancer, offering novel intervention targets and translational strategies to overcome therapeutic resistance in HCC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.